# OnCo record nct05194995 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05194995/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05194995", "NCT05194995" ;
  schema:name "JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation"@en ;
  schema:description "A phase 1/2 trial of Glecirasib, Cetuximab in colorectal cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05194995/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05194995> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-02-17" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/kras-g12c-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/drugs/cetuximab/> ;
  onco:companies <https://onco.cc/companies/allist/> .